All news

Genes determine trastuzumab response in breast cancer trial

Added: Monday 2 February 2015

Research into the effects of trastuzumab (also known as herceptin) finds that genes relating to patient immune function were key to determining response to the drug. The research was done on patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer. Those with high levels of immune genes had greater relapse-free survival on trastuzumab than those without.